The Evaluation of the Safety and Efficacy of Sustained Release Dexamethasone Intracanalicular Insert (DEXTENZA) in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia (TENDER)

Status: Completed
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY

The Tender Study is a prospective, open-label, single-center, randomized, investigator-initiated clinical study seeks to investigate the safety and efficacy of the DEXTENZA insert in pediatric patients following retinal surgery or laser treatment under anesthesia.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 3
Maximum Age: 17
Healthy Volunteers: t
View:

⁃ Pediatric patients undergoing routine retinal surgery or laser treatment under anesthesia for a variety of visual conditions. These conditions and procedures include but are not limited to:

⁃ Conditions:

• Familial Exudative Vitreoretinopathy

• Coats' Disease

• Exudative Retinopathy

• Lattice degeneration

• Retinal holes

• Sickler's syndrome

• Retinal detachment, rhegmatogenous

• Retinal detachment, exudative

• Retinal detachment, tractional

⁃ Procedures

• Laser photocoagulation

• Cryotherapy

• Retinal detachment repair with scleral buckle and cryotherapy

• Retinal detachment repair with vitrectomy

• Written informed consent from parent/legal guardian

Locations
United States
North Carolina
Duke Eye Center
Durham
Time Frame
Start Date: 2023-02-01
Completion Date: 2025-02-24
Participants
Target number of participants: 16
Treatments
Experimental: Treatment Arm
Dextenza insert intraoperatively for perioperative ocular inflammation and pain. These patients will not be prescribed topical steroid drops post-operatively
Active_comparator: Control Arm
Prednisolone forte 1% steroid drop taper for 28 days post-operatively to treat perioperative ocular inflammation and pain; drops four times per day (QUID) on days 0-7, three times per day (TID) on days 7-14, twice per day (BID) on days 14-21 and once per day (QD) on days 21-28.
Sponsors
Leads: Lejla Vajzovic, MD, FASRS

This content was sourced from clinicaltrials.gov

Similar Clinical Trials